Rijeka Danas
Serum od 23 eura koji zamjenjuje puder postao hit na TikToku | Rijeka Danas
Serum od 23 eura koji zamjenjuje puder postao hit na TikToku | Posljednjih mjeseci na društvenim mrežama vlada pravi boom oko pristupačnog seruma The…
375
7k
4k
647k
Dermatologist's $22 Skincare Recommendation: A Game-Changer or a Conflict of Interest?
Dermatologist's "Hot Take" on Skincare Sparks Debate Over Affordable Exosome Serum A recent viral video by dermatologist Dr. Lejla, known as TheBeautyDerm, has ignited discussion within the skincare community by promoting an affordable exosome serum as a viable alternative to expensive in-office treatments. In her video, Dr. Lejla declared, "You don't need a $300 facial to get glowing, radiant skin because this serum right here gives you those same results for $22." The product in question is The INKEY List Exosome Hydro-Glow Serum, which Dr. Lejla claims is "packed with exosomes, aka the game-changing ingredient behind in-office treatments." She highlighted its benefits, including boosting collagen, reducing inflammation, firming skin, and providing barrier support, all without irritation or a greasy feel. However, the video, explicitly marked as a "paid partnership" with The INKEY List, has drawn mixed reactions from viewers. While many expressed excitement about an accessible exosome product, some comments questioned the efficacy of plant-derived exosomes compared to human exosomes, and raised concerns about dermatologists engaging in paid endorsements. One commenter stated, "I’m getting really sick of literal doctors taking a paid partnership. This is disgusting, how can I take anything you say seriously?" Another queried, "does it have growth factors in it and if so, doesn't growth factors promote some cancers?" The debate underscores a growing tension between expert endorsements, product affordability, and consumer trust in the rapidly evolving beauty industry. The INKEY List serum is now available at Sephora, prompting consumers to weigh the expert recommendation against their own research and skepticism regarding commercial partnerships.
